open access
Endophthalmitis — a rare but dangerous complication of intravitreal anti-VEGF injections
, 2, 2, 1, 2
Affiliations- Students’ Research Group at the Chair and Department of General and Paediatric Ophthalmology, Medical University of Lublin, Lublin Poland
- Students’ Scientific Association at the Department of Epidemiology and Clinical Research Methodology, Medical University of Lublin, Lublin Poland
open access
Abstract
Agents blocking vascular endothelial growth factor (anti-VEGF) — aflibercept, bevacizumab, and ranibizumab are commonly used drugs in the treatment of retinal vascular diseases, including age-related macular degeneration, diabetic retinopathy, retinal vascular occlusions and retinopathy of prematurity. To date, intravitreal injection is the only successful administration method of anti-VEGF agents. Each administration can potentially lead to rhegmatogenous retinal detachment, intraocular pressure elevation, ocular hemorrhage, and endophthalmitis. Endophthalmitis is a rare complication, occurring in 0.012–0.1% of cases of anti-VEGF injections. The most frequent isolated pathogens are Staphylococcus spp. and Streptococcus viridans — commensals of the human upper respiratory and oral flora. The main symptoms of endophthalmitis are pain and decreased visual acuity. Patients become symptomatic on average three days after the injection. Prevention of endophthalmitis includes sterilization of ocular surface with povidone-iodine, use of sterile gloves, use of eye speculum, and „no-talking” policy. Topical antibiotics are not routinely used as they can even increase the risk of post-injection endophthalmitis. It is essential to estimate the risk factors and prevention methods to reduce post-injection endophthalmitis rates in the future.
Abstract
Agents blocking vascular endothelial growth factor (anti-VEGF) — aflibercept, bevacizumab, and ranibizumab are commonly used drugs in the treatment of retinal vascular diseases, including age-related macular degeneration, diabetic retinopathy, retinal vascular occlusions and retinopathy of prematurity. To date, intravitreal injection is the only successful administration method of anti-VEGF agents. Each administration can potentially lead to rhegmatogenous retinal detachment, intraocular pressure elevation, ocular hemorrhage, and endophthalmitis. Endophthalmitis is a rare complication, occurring in 0.012–0.1% of cases of anti-VEGF injections. The most frequent isolated pathogens are Staphylococcus spp. and Streptococcus viridans — commensals of the human upper respiratory and oral flora. The main symptoms of endophthalmitis are pain and decreased visual acuity. Patients become symptomatic on average three days after the injection. Prevention of endophthalmitis includes sterilization of ocular surface with povidone-iodine, use of sterile gloves, use of eye speculum, and „no-talking” policy. Topical antibiotics are not routinely used as they can even increase the risk of post-injection endophthalmitis. It is essential to estimate the risk factors and prevention methods to reduce post-injection endophthalmitis rates in the future.
Keywords
endophthalmitis; anti-VEGF injections; post-injection endophthalmitis
About this articleTitle
Endophthalmitis — a rare but dangerous complication of intravitreal anti-VEGF injections
Journal
Issue
Vol 8 (2023): Continuous Publishing
Article type
Review paper
Pages
52-55
Published online
2023-05-02
Page views
1876
Article views/downloads
421
DOI
Bibliographic record
Ophthalmol J 2023;8:52-55.
Keywords
endophthalmitis
anti-VEGF injections
post-injection endophthalmitis
Authors
Karolina Urbańska
Julita Szarpak
Natalia Biel
Marcin Woźniak
Weronika Kawecka
References (31)- Falavarjani KG, Nguyen QD. Adverse events and complications associated with intravitreal injection of anti-VEGF agents: a review of literature. Eye (Lond). 2013; 27(7): 787–794.
- Pancholy M, Storey PP, Levin HJ, et al. Endophthalmitis following Intravitreal Anti-Vascular Endothelial Growth Factor Therapy: Changes in Incidence and Outcomes over a 9-Year Period. Curr Eye Res. 2021; 46(9): 1370–1377.
- Seah I, Zhao X, Lin Q, et al. Use of biomaterials for sustained delivery of anti-VEGF to treat retinal diseases. Eye (Lond). 2020; 34(8): 1341–1356.
- Shah CP, Garg SJ, Vander JF, et al. Post-Injection Endophthalmitis (PIE) Study Team. Outcomes and risk factors associated with endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor agents. Ophthalmology. 2011; 118(10): 2028–2034.
- Kiss S, Dugel PU, Khanani AM, et al. Endophthalmitis rates among patients receiving intravitreal anti-VEGF injections: a USA claims analysis. Clin Ophthalmol. 2018; 12: 1625–1635.
- Busch C, Iglicki M, Okada M, et al. for the International Retina Group (IRG). Causative Pathogens of Endophthalmitis after Intravitreal Anti-VEGF Injection: An International Multicenter Study. Ophthalmologica. 2019; 241(4): 211–219.
- Hoevenaars NED, Gans D, Missotten T, et al. Suspected bacterial endophthalmitis following intravitreal anti-VEGF injection: case series and literature review. Ophthalmologica. 2012; 228(3): 143–147.
- Labardini CP, Blumenthal EZ. Causative Pathogens in Endophthalmitis after Intravitreal Injection of Anti-vascular Endothelial Growth Factor Agents. Rambam Maimonides Med J. 2018 [Epub ahead of print]; 9(4): 1–6.
- Fileta JB, Scott IU, Flynn HW. Meta-analysis of infectious endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor agents. Ophthalmic Surg Lasers Imaging Retina. 2014; 45(2): 143–149.
- Matthews JL, Dubovy SR, Goldberg RA, et al. Histopathology of streptococcus mitis/oralis endophthalmitis after intravitreal injection with bevacizumab: a report of 7 patients. Ophthalmology. 2014; 121(3): 702–708.
- Goldberg RA, Flynn HW, Isom RF, et al. An outbreak of streptococcus endophthalmitis after intravitreal injection of bevacizumab. Am J Ophthalmol. 2012; 153(2): 204–208.e1.
- Pietras-Baczewska A, Jasińska E, Toro MD, et al. Urgent Vitrectomy with Vancomycin Infusion, Silicone Oil Endotamponade, and General Antibiotic Treatment in Multiple Cases of Endophthalmitis from a Single Day of Intravitreal Injections-Case Series. J Clin Med. 2021; 10(5).
- Cox JT, Eliott D, Sobrin L. Inflammatory Complications of Intravitreal Anti-VEGF Injections. J Clin Med. 2021; 10(5).
- Storey PP, Patel D, Garg S. Endophthalmitis following intravitreal injection of anti-vascular endothelial growth factor agents. Can J Ophthalmol. 2020; 55(4): 286–292.
- Rejdak R, Choragiewicz T, Kalinowska A, et al. Vancomycin in infusion during vitrectomy in surgical treatment of acute postoperative and posttraumatic endophthalmitis. BMC Infect Dis. 2016; 16: 496.
- Dave VP, Joseph J, Jayabhasker P, et al. Does ophthalmic-grade silicone oil possess antimicrobial properties? J Ophthalmic Inflamm Infect. 2019; 9(1): 20.
- Ornek N, Apan T, Oğurel R, et al. Comparison of the antimicrobial effect of heavy silicone oil and conventional silicone oil against endophthalmitis-causing agents. Indian J Ophthalmol. 2014; 62(4): 388–391.
- Yospaiboon Y, Meethongkam K, Sinawat S, et al. Predictive factors in the treatment of streptococcal endophthalmitis. Clin Ophthalmol. 2018; 12: 859–864.
- Yannuzzi NA, Gregori NZ, Rosenfeld PJ, et al. Endophthalmitis Associated With Intravitreal Injections of Anti-VEGF Agents at a Tertiary Referral Center: In-House and Referred Cases. Ophthalmic Surg Lasers Imaging Retina. 2018; 49(5): 313–319.
- Scott IU, Flynn HW. Reducing the risk of endophthalmitis following intravitreal injections. Retina. 2007; 27(1): 10–12.
- Patel SN, Storey PP, Kim JS, et al. Systemic Immunosuppression and Risk of Endophthalmitis After Intravitreal Anti-Vascular Endothelial Growth Factor Injections. Ophthalmic Surg Lasers Imaging Retina. 2021; 52(S1): S17–S22.
- Stem MS, Rao P, Lee IJ, et al. Predictors of Endophthalmitis after Intravitreal Injection: A Multivariable Analysis Based on Injection Protocol and Povidone Iodine Strength. Ophthalmol Retina. 2019; 3(1): 3–7.
- Morioka M, Takamura Y, Nagai K, et al. Incidence of endophthalmitis after intravitreal injection of an anti-VEGF agent with or without topical antibiotics. Sci Rep. 2020; 10(1): 22122.
- Bande MF, Mansilla R, Pata MP, et al. Intravitreal injections of anti-VEGF agents and antibiotic prophylaxis for endophthalmitis: A systematic review and meta-analysis. Sci Rep. 2017; 7(1): 18088.
- Milder E, Vander J, Shah C, et al. Changes in antibiotic resistance patterns of conjunctival flora due to repeated use of topical antibiotics after intravitreal injection. Ophthalmology. 2012; 119(7): 1420–1424.
- Lau PEt, Jenkins KS, Layton CJ. Current Evidence for the Prevention of Endophthalmitis in Anti-VEGF Intravitreal Injections. J Ophthalmol. 2018; 2018: 8567912.
- Fineman MS, Hsu J, Spirn MJ, et al. Bimanual assisted eyelid retraction technique for intravitreal injections. Retina. 2013; 33(9): 1968–1970.
- Chen E, Lin MY, Cox J, et al. Endophthalmitis after intravitreal injection: the importance of viridans streptococci. Retina. 2011; 31(8): 1525–1533.
- Li T, Sun J, Min J, et al. Safety of Receiving Anti-Vascular Endothelial Growth Factor Intravitreal Injection in Office-Based vs Operating Room Settings: A Meta-analysis. JAMA Ophthalmol. 2021; 139(10): 1080–1088.
- Reyes-Capo DP, Yannuzzi NA, Smiddy WE, et al. Endophthalmitis/Anti-VEGF Study Group*. Trends in Endophthalmitis Associated With Intravitreal Injection of Anti-VEGF Agentsat a Tertiary Referral Center. Ophthalmic Surg Lasers Imaging Retina. 2021; 52(6): 319–326.
- Hébert M, You E, Hammamji K, et al. Impact of patient face mask use on endophthalmitis after intravitreal anti-VEGF injections. Can J Ophthalmol. 2022; 57(6): 364–369.